Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. a “real life” retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy
- Publication date
- 1 January 2016
- Publisher
- 'American Society of Clinical Oncology (ASCO)'